Impact of Results From the COVID-19 in MS Global Data-Sharing Initiative
COVID-19 in MS Global Data-Sharing Initiative Anti-CD20 Therapy Results
CLARITY Extension Trial: Disability Improvement With Cladribine
Chief Endpoints and Potential Significance: Phase 3b OLIKOS Trial
Ofatumumab vs Teriflunomide: Phase 3 ASCLEPIOS I/II Open-Label Extension Study
Key Takeaways from the 8th ACTRIMS-ECTRIMS 2020 Meeting
Ozanimod Compared to Teriflunomide Utilizing Statistical Matching
OPTIMUM Phase 3 Trial: Ponesimod’s Cardiac Safety Data
OLKIOS Phase 3b Trial: Pivotal Endpoints and Potential Significance
Phase 3 ASCLEPIOS I/II Open-Label Extension Study: Ofatumumab vs Teriflunomide
Takeaways From ACTRIMS-ECTRIMS 2020 Meeting
Rationale for Selected Dosing Regimen of Evobrutinib in Phase 3 Studies
OPTIMUM: Ponesimod Superiority in MRI-based Outcomes in RRMS
OLKIOS: Looking at Ofatumumab’s Continued Efficacy
Ofatumumab vs Teriflunomide: ASCLEPIOS I/II RMS Trials
